{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:02:04Z","timestamp":1790694124028,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["LKLY25H160006"],"award-info":[{"award-number":["LKLY25H160006"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470182"],"award-info":[{"award-number":["82470182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008327","name":"Zhejiang University of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003786","name":"Hangzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2025SZD1B13"],"award-info":[{"award-number":["2025SZD1B13"]}],"id":[{"id":"10.13039\/501100003786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.isci.2026.115174","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:12:42Z","timestamp":1772295162000},"page":"115174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma"],"prefix":"10.1016","volume":"29","author":[{"given":"Lingli","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7772-220X","authenticated-orcid":false,"given":"Shibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.115174_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.isci.2026.115174_bib2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2026.115174_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174082","article-title":"Multiple Myeloma Therapy: Emerging Trends and Challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.115174_bib4","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"Bmj"},{"key":"10.1016\/j.isci.2026.115174_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2016.152504","article-title":"Is immunotherapy here to stay in multiple myeloma?","volume":"102","author":"Rodr\u00edguez-Otero","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.115174_bib6","article-title":"Therapeutic strategies to enhance immune response induced by multiple myeloma cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115174_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1532","article-title":"CD47 overexpression is related to tumour-associated macrophage infiltration and diffuse large B-cell lymphoma progression","volume":"14","author":"Shen","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.isci.2026.115174_bib8","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.115174_bib9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.115174_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.115174_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.058","article-title":"Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection","volume":"31","author":"Cham","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.115174_bib12","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.115174_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.115174_bib14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115174_bib15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.isci.2026.115174_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.isci.2026.115174_bib17","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115174_bib18","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115174_bib19","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115174_bib20","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115174_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.943","article-title":"CD47-SIRP\u03b1 blocking-based immunotherapy: Current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.isci.2026.115174_bib22","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2026.115174_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01399-4","article-title":"A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115174_bib24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/19420862.2015.1062192","article-title":"A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells","volume":"7","author":"Piccione","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2026.115174_bib25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1535-7163.MCT-19-1079","article-title":"Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2026.115174_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2026.115174_bib27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic Viruses in Cancer Treatment: A Review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.115174_bib28","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115174_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.115174_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115174_bib31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115174_bib32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s43018-022-00448-0","article-title":"Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity","volume":"3","author":"Tian","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2026.115174_bib33","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An Oncolytic Virus Expressing IL15\/IL15R\u03b1 Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.115174_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.115174_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-022-00634-4","article-title":"CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma","volume":"12","author":"Lei","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.115174_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103240","article-title":"Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)","volume":"64","author":"Zuo","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2026.115174_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009473","article-title":"Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.115174_bib38","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3324\/haematol.2024.286923","article-title":"An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment","volume":"110","author":"Li","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.115174_bib39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.115174_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2050-7771-1-13","article-title":"The resistance mechanisms of proteasome inhibitor bortezomib","volume":"1","author":"L\u00fc","year":"2013","journal-title":"Biomark. Res."},{"key":"10.1016\/j.isci.2026.115174_bib41","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41388-021-02167-9","article-title":"Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.115174_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.isci.2026.115174_bib43","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.7150\/thno.15584","article-title":"Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma","volume":"6","author":"Roy","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.isci.2026.115174_bib44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/1878-0261.12641","article-title":"NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma","volume":"14","author":"Xia","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.isci.2026.115174_bib45","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41392-023-01683-2","article-title":"Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.115174_bib46","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115174_bib47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mt.2015.156","article-title":"Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses","volume":"24","author":"Rajani","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115174_bib48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12951-024-02903-9","article-title":"Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.isci.2026.115174_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194703","article-title":"Dual-Armed Oncolytic Myxoma Virus Encoding IFN-\u03b3 and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma","volume":"15","author":"Woo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.115174_bib50","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115174_bib51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1158\/1078-0432.CCR-21-1248","article-title":"Targeting Fc Receptor-Mediated Effects and the \u201cDon\u2019t Eat Me\u201d Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer","volume":"28","author":"Tian","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226005493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226005493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:48:07Z","timestamp":1790693287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226005493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2589004226005493"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.115174","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.115174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115174"}}